Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2007 2
2008 1
2009 3
2010 2
2011 1
2012 5
2013 4
2014 1
2015 3
2016 2
2017 1
2018 2
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, Coma S, Kumada Y, Yamany MS, Sentandreu E, Fromm G, Tiziani S, Schreiber TH, Manfredi M, Ehrlich LIR, Stone E, Georgiou G. Triplett TA, et al. Among authors: schreiber th. Nat Biotechnol. 2018 Sep;36(8):758-764. doi: 10.1038/nbt.4180. Epub 2018 Jul 16. Nat Biotechnol. 2018. PMID: 30010674 Free PMC article.
Immunological mechanisms of the antitumor effects of supplemental oxygenation.
Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, Thayer M, Rodig S, Kutok JL, Jackson EK, Karger B, Podack ER, Ohta A, Sitkovsky MV. Hatfield SM, et al. Among authors: schreiber th. Sci Transl Med. 2015 Mar 4;7(277):277ra30. doi: 10.1126/scitranslmed.aaa1260. Sci Transl Med. 2015. PMID: 25739764 Free PMC article.
Immunobiology of TNFSF15 and TNFRSF25.
Schreiber TH, Podack ER. Schreiber TH, et al. Immunol Res. 2013 Dec;57(1-3):3-11. doi: 10.1007/s12026-013-8465-0. Immunol Res. 2013. PMID: 24242819 Review.
The role of TNFRSF25:TNFSF15 in disease… and health?
Schreiber TH, Wolf D, Podack ER. Schreiber TH, et al. Adv Exp Med Biol. 2011;691:289-98. doi: 10.1007/978-1-4419-6612-4_30. Adv Exp Med Biol. 2011. PMID: 21153333 Review. No abstract available.
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G, de Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH. Fromm G, et al. Among authors: schreiber th. J Immunother Cancer. 2018 Dec 18;6(1):149. doi: 10.1186/s40425-018-0454-3. J Immunother Cancer. 2018. PMID: 30563566 Free PMC article.
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page